How AstraZeneca plc Can Pay Off Your Mortgage

AstraZeneca plc (LON: AZN) has potential. And it could help pay off your mortgage. Here’s how.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

AstraZenecaWhat a difference a year makes! Shares in AstraZeneca (LSE: AZN) (NYSE: AZN.US) are now 30% higher than they were just one year ago, with the performance of the pharmaceutical company easily beating the 1% gains of the FTSE 100 over the same time period.

So, what’s changed? Clearly, AstraZeneca’s share price has benefited hugely from the bid approaches from Pfizer, with it still appearing to include a takeover premium of sorts. However, this isn’t the full story, since the market’s perception of where AstraZeneca is headed has changed considerably since a year ago, with the future now looking a lot brighter. As such, AstraZeneca could be a great long-term play.

Falling Earnings

Of course, the ‘patent cliff’ still exists, where AstraZeneca is due to lose patent protection on a number of key, blockbuster drugs in the short run. This has hurt profits and will continue to do so for another couple of years. Indeed, AstraZeneca’s earnings per share (EPS) fell by 26% last year and are forecast to drop by another 14% in the current year. Although better, next year is still due to see a fall of 3%, which shows that the company remains in a difficult place right now.

Future Potential

However, AstraZeneca’s future looks much brighter now than a year or two ago. That’s because it has focused on rejuvenating its drug pipeline through a number of key acquisitions. An example is the purchase of Bristol-Myers Squibb‘s half of the two companies’ diabetes joint venture. This should help AstraZeneca to grow the top and bottom line over the long run, as the number of people with diabetes in the US alone is set to increase by 165% from the year 2000 to the year 2050. Further deals look likely, with AstraZeneca’s new management team ending the superfluous share buyback scheme. This allows more capital to be spent on developing the drug pipeline.

Looking Ahead

Certainly, AstraZeneca’s share price is not as attractive at £43 as it was at £33 one year ago. However, the company is in better shape and so the current price to earnings (P/E) ratio of 17.1 does not appear to be excessive for long-term investors. Clearly, a lack of further bid activity could cause the share price to weaken in the short run, but with an improving pipeline and the scope for more acquisitions, AstraZeneca could be a long-term winner and, as such, could help to pay off your mortgage.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares in AstraZeneca. The Motley Fool has no position in any of the shares mentioned.

More on Investing Articles

Tesla car at super charger station
US Stock

£1k invested in Tesla stock at the start of the year is currently worth…

Jon Smith reveals the performance of Tesla stock in 2025 and explains why he doesn't believe the move lower is…

Read more »

Woman riding her old fashioned bicycle along the Beach Esplanade at Aberdeen, Scotland.
Investing Articles

What sort of return could someone get by investing £20,000 in UK dividend shares?

Should UK savers consider dividend shares over cash? Stephen Wright thinks those looking for long-term passive income would be wise…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Around a 15-year high, is Barclays’ share price still too cheap to ignore?

Barclays’ share price is at a level not seen since 2010, but price and value aren't the same thing, so…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

47% below fair value and with an 18% earnings growth forecast, should investors consider this FTSE retail institution now?

This FTSE 100 British retail institution lost its way for a while but has bounced back in recent years, and…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Lloyds share price: up 40% this year, is it time to take profits?

The booming Lloyds share price is up nearly 40% in 2025, outperforming its UK banking peers. Our writer asks whether…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

If the stock market crashes tomorrow, here’s what I’ll do with my portfolio

A stock market crash can feel terrifying. Here’s why staying calm matters – and how this recovering FTSE 100 company…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Prediction: in 12 months the smashed up Diageo share price could transform £10,000 into…

Harvey Jones has taken a big hit on his Diageo shares but forecasts suggest next year may offer something to…

Read more »

Aviva logo on glass meeting room door
Investing Articles

Will the Aviva share price reach £10? Here’s what needs to happen

With profits potentially set to double by the end of 2026, could the Aviva share price do the same and…

Read more »